Business
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
- The collaboration is expected to examine the most common solid tumors in order to determine the patient populations most likely to benefit from LP-100
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- The collaboration is expected to examine the most common solid tumors in order to determine the patient populations most likely to benefit from LP-100 (irofulven) and LP-184\n - LP-100 and LP-184 have both shown synthetically lethal impact in tumors that are lacking nucleotide excision repair (NER) capabilities\n - The collaboration aims to provide a comprehensive analysis of the role of NER deficiency in breast, ovarian, prostate, lung, kidney, bladder, stomach, pancreatic and esophageal cancer\n\n\nDALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to identify nucleotide excision repair (NER) deficient tumors. LP-100 and LP-184 have both shown synthetically lethal impact in tumors that are lacking NER capabilities. The DCRC is a cancer research institute within the Danish Cancer Society. The Danish Cancer Society is Denmark's largest non-government organization and dedicates more than 60% of its budget to research, with the remainder shared between prevention and patient support initiatives. Lantern expects the data, genomic signatures and biological models generated from this collaboration to add millions of data points to RADR® and help accelerate the development of new indications for LP-100 and LP-184. This collaboration, together with the growing power of the RADR® platform, can potentially uncover new drug combinations using LP-100 and LP-184 for cancer treatments at a fraction of the cost of traditional drug development. \n\n \n \n \n \n \n \n\n \nThe overall aim of the collaboration is to determine the most promising patient populations for future LP-100 (irofulven) and LP-184 therapy. The collaboration will focus on developing improved diagnostic tools to detect NER deficiency patient profiles more accurately. The research study conducted as part of the collaboration will use expanded mutational signature-based analyses to achieve this obje...